Array BioPharma Announces Clinical Data Presentation On ARRY-797 At The 2016 European Society Of Cardiology Congress
BOULDER, Colo., Aug. 19, 2016 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from a Phase 2 study of ARRY-797 will be presented at the 2016 European Society of Cardiology (ESC) Congress, which will be held August 27 – 31, 2016 in Rome, Italy.
POSTER PRESENTATION
| Title: |
Phase 2 study of A797, an oral, selective p38 mitogen-activated protein kinase inhibitor, in patients with lamin A/C-related dilated cardiomyopathy (Abstract #P4981) |
| Presenter: |
Calum A. MacRae, MD |
| Date: |
Tuesday, August 30, 10:19 a.m. CEST |
Updated and additional data will be provided at the conference beyond what is included in the abstract.
All abstracts can be accessed through the ESC website, or on this web page: http://spo.escardio.org/default.aspx?eevtid=1127.
The ARRY-797 abstract can be found by clicking this LINK.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Five registration studies are currently advancing related to three cancer drugs. These programs include binimetinib (MEK162), encorafenib (LGX818) and selumetinib (AstraZeneca). For more information on Array, please go to www.arraybiopharma.com.
| CONTACT: |
Tricia Haugeto |
| (303) 386-1193 |
|
Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
SOURCE Array BioPharma
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article